Moreover, recent preclinical data confirm that FGFR inhibition in FGFR3-mutant urothelial carcinoma abolishes immunosuppression and increases the efficacy of anti-PD-1 agents [118]. This evidence concerns the gene FGFR3 and urothelial carcinoma.